Donaldson Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$105M Buy
482,055
+3,418
+0.7% +$758K 3.39% 5
2025
Q4
$109M Sell
478,637
-3,594
-0.7% -$819K 3.48% 7
2025
Q3
$112M Buy
482,231
+4,744
+1% +$966K 3.54% 6
2025
Q2
$88.6M Sell
477,487
-3,145
-0.7% -$584K 3.25% 7
2025
Q1
$101M Buy
480,632
+10,896
+2% +$2.12M 3.8% 4
2024
Q4
$83.5M Buy
469,736
+1,124
+0.2% +$207K 3.19% 6
2024
Q3
$92.5M Buy
468,612
+3,643
+0.8% +$680K 3.56% 5
2024
Q2
$79.8M Sell
464,969
-8,455
-2% -$1.4M 3.35% 6
2024
Q1
$86.2M Buy
473,424
+2,224
+0.5% +$383K 3.59% 5
2023
Q4
$73M Sell
471,200
-12,194
-3% -$1.78M 3.27% 6
2023
Q3
$72.1M Buy
483,394
+5,417
+1% +$795K 3.39% 4
2023
Q2
$64.4M Buy
477,977
+5,311
+1% +$779K 2.94% 7
2023
Q1
$75.3M Buy
472,666
+2,896
+0.6% +$443K 3.56% 3
2022
Q4
$75.9M Buy
469,770
+7,287
+2% +$1.12M 3.7% 3
2022
Q3
$62.1M Buy
462,483
+5,233
+1% +$751K 3.41% 4
2022
Q2
$70M Sell
457,250
-99,622
-18% -$15.2M 3.6% 3
2022
Q1
$90.3M Sell
556,872
-436
-0.1% -$63.3K 4.11% 3
2021
Q4
$75.5M Buy
557,308
+8,879
+2% +$1.05M 3.32% 6
2021
Q3
$59.2M Buy
548,429
+6,756
+1% +$772K 2.98% 6
2021
Q2
$61M Buy
541,673
+11,929
+2% +$1.34M 3.12% 4
2021
Q1
$57.3M Buy
529,744
+7,936
+2% +$849K 3.15% 3
2020
Q4
$55.9M Sell
521,808
-1,291
-0.2% -$124K 3.31% 4
2020
Q3
$45.8M Sell
523,099
-11,217
-2% -$1.06M 3.1% 7
2020
Q2
$52.5M Buy
534,316
+5,325
+1% +$469K 3.81% 3
2020
Q1
$40.3M Buy
528,991
+35,961
+7% +$3.06M 3.52% 4
2019
Q4
$43.7M Buy
493,030
+11,093
+2% +$921K 2.95% 5
2019
Q3
$36.5M Buy
481,937
+100,832
+26% +$6.91M 2.71% 10
2019
Q2
$27.7M Buy
381,105
+8,901
+2% +$700K 2.3% 24
2019
Q1
$30M Sell
372,204
-20,431
-5% -$1.67M 2.67% 16
2018
Q4
$36.2M Buy
392,635
+158
+0% +$13.9K 3.69% 3
2018
Q3
$37.1M Sell
392,477
-1,246
-0.3% -$118K 3.24% 6
2018
Q2
$36.5M Sell
393,723
-4,514
-1% -$441K 3.56% 4
2018
Q1
$37.7M Sell
398,237
-12,812
-3% -$1.41M 3.71% 2
2017
Q4
$39.8M Sell
411,049
-6,823
-2% -$643K 3.88% 1
2017
Q3
$37.1M Sell
417,872
-1,059
-0.3% -$80.6K 3.9% 1
2017
Q2
$30.4M Sell
418,931
-8,853
-2% -$595K 3.44% 4
2017
Q1
$27.9M Sell
427,784
-8,646
-2% -$544K 3.24% 10
2016
Q4
$27.3M Buy
436,430
+170
+0% +$10.4K 3.36% 4
2016
Q3
$27.5M Buy
436,260
+9,040
+2% +$585K 3.64% 3
2016
Q2
$26.4M Buy
427,220
+11,450
+3% +$698K 3.67% 3
2016
Q1
$23.7M Sell
415,770
-2,985
-0.7% -$166K 3.42% 6
2015
Q4
$24.8M Buy
418,755
+771
+0.2% +$44.4K 3.63% 4
2015
Q3
$22.7M Sell
417,984
-722
-0.2% -$47K 3.39% 4
2015
Q2
$28.1M Buy
418,706
+12,553
+3% +$820K 4% 1
2015
Q1
$23.8M Buy
406,153
+68,271
+20% +$4.12M 3.35% 2
2014
Q4
$22.1M Sell
337,882
-94
-0% -$5.93K 3.3% 7
2014
Q3
$19.5M Buy
337,976
+11,704
+4% +$650K 3.09% 10
2014
Q2
$18.4M Buy
326,272
+12,492
+4% +$655K 2.95% 8
2014
Q1
$16.1M Buy
313,780
+10,930
+4% +$552K 2.92% 12
2013
Q4
$16M Buy
302,850
+22,381
+8% +$1.1M 3.09% 10
2013
Q3
$12.5M Buy
280,469
+2,698
+1% +$120K 2.65% 17
2013
Q2
$11.5M Buy
+277,771
New +$12.1M 2.6% 20

Other funds holding ABBV

Donaldson Capital Management's ABBV Position: Q1 2026 in Review

Donaldson Capital Management increased its AbbVie (ABBV) stake by 0.71% in Q1 2026, buying an estimated $758K and bringing the position to 482,055 shares worth $105M. The position accounts for 3.39% of the portfolio, ranked #5.

Donaldson Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $112M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Donaldson Capital Management held 482,055 shares of AbbVie worth $105M as of Q1 2026.
  • Donaldson Capital Management bought 3,418 AbbVie shares in Q1 2026, an estimated $758K.
  • AbbVie made up 3.39% of Donaldson Capital Management's portfolio in Q1 2026, its #5 holding.
  • Donaldson Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Donaldson Capital Management's AbbVie position peaked at $112M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Donaldson Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.